We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+21.91%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$154M
AUM Growth
-$35M
Cap. Flow
-$41.2M
Cap. Flow %
-26.76%
Top 10 Hldgs %
66.56%
Holding
37
New
5
Increased
7
Reduced
9
Closed
11

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$17M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$8.18M
3
RZLT icon
Rezolute
RZLT
+$8.17M
4
LEGN icon
Legend Biotech
LEGN
+$6.86M
5
AKRO
Akero Therapeutics
AKRO
+$4.72M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$10.1M
2
MRUS
Merus
MRUS
+$9.98M
3
KALV
KalVista Pharmaceuticals
KALV
+$8.45M
4
AKBA icon
Akebia Therapeutics
AKBA
+$8.21M
5
ASND icon
Ascendis Pharma A/S
ASND
+$7.79M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$9.35B
$19.8M 12.84%
500,000
+250,000
+100% +$8.18M
RZLT icon
2
Rezolute
RZLT
$480M
$13.5M 8.8%
3,033,462
+2,200,420
+264% +$8.17M
AMLX icon
3
Amylyx Pharmaceuticals
AMLX
$2.05B
$12.8M 8.34%
2,000,000
+188,004
+10% +$914K
LEGN icon
4
Legend Biotech
LEGN
$4.3B
$12.4M 8.08%
350,000
+211,760
+153% +$6.86M
ABVX
5
Abivax
ABVX
$11B
$9.88M 6.42%
1,291,617
-346,494
-21% -$2.26M
NGNE icon
6
Neurogene
NGNE
$696M
$7.26M 4.72%
485,859
+14,895
+3% +$234K
AKBA icon
7
Akebia Therapeutics
AKBA
$327M
$7.23M 4.7%
1,985,915
-2,987,925
-60% -$8.21M
EOLS icon
8
Evolus
EOLS
$394M
$6.63M 4.31%
720,118
-224,625
-24% -$2.3M
ACLX
9
DELISTED
Arcellx
ACLX
$6.58M 4.28%
100,000
+55,000
+122% +$3.42M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.32B
$6.26M 4.07%
200,000
-45,272
-18% -$1.48M
AKRO
11
DELISTED
Akero Therapeutics
AKRO
$5.54M 3.6%
+103,848
New +$4.72M
JBIO
12
Jade Biosciences
JBIO
$1.22B
$4.98M 3.24%
+498,054
New +$17M
CYTK icon
13
Cytokinetics
CYTK
$11B
$4.96M 3.22%
150,000
-220,000
-59% -$7.65M
IMVT icon
14
Immunovant
IMVT
$8.09B
$4.19M 2.73%
262,176
-112,824
-30% -$1.71M
UNCY icon
15
Unicycive Therapeutics
UNCY
$148M
$3.8M 2.47%
796,558
-301,442
-27% -$1.86M
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$3.65M 2.38%
323,170
-691,197
-68% -$8.45M
TSHA icon
17
Taysha Gene Therapies
TSHA
$1.59B
$3.46M 2.25%
+1,500,000
New +$3.26M
DBVT
18
DBV Technologies
DBVT
$807M
$3.43M 2.23%
+374,679
New +$3.31M
ZURA icon
19
Zura Bio
ZURA
$497M
$3.33M 2.16%
3,170,194
– –
UPB
20
Upstream Bio Inc
UPB
$349M
$3.29M 2.14%
300,000
– –
CNTX icon
21
Context Therapeutics
CNTX
$56.4M
$3.07M 2%
4,683,711
– –
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$2.96M 1.92%
225,000
+75,298
+50% +$954K
SRRK icon
23
Scholar Rock
SRRK
$5.71B
$2.18M 1.42%
+61,607
New +$1.93M
PMN icon
24
ProMIS Neurosciences
PMN
$109M
$1.28M 0.83%
105,805
– –
PLRX icon
25
Pliant Therapeutics
PLRX
$67.5M
$986K 0.64%
850,000
– –
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Great Point Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Great Point Partners held 37 positions worth $154M, down 19% from $189M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Great Point Partners withdrew a net $41.2M in Q2 2025, closing 11 positions and reducing 9 holdings. Its most notable exit was Viridian Therapeutics, an estimated $10.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Jade Biosciences worth $4.98M.

  • Great Point Partners's largest Q2 2025 buy was Jade Biosciences: 498,054 shares worth $4.98M.
  • Great Point Partners added most to Ionis Pharmaceuticals in Q2 2025, an estimated $8.18M increase.
  • Great Point Partners's biggest Q2 2025 reduction was KalVista Pharmaceuticals, cutting an estimated $8.45M.
  • Great Point Partners fully exited Viridian Therapeutics in Q2 2025, selling an estimated $10.1M.
  • Great Point Partners's ten largest holdings make up 67% of its $154M portfolio in Q2 2025.
  • Great Point Partners opened 5 new positions and closed 11 in Q2 2025.
  • Great Point Partners's portfolio value fell 19% quarter-over-quarter to $154M.

Based on Great Point Partners's 13F filing for Q2 2025, filed 14 Aug 2025.